Florida sues Merck over Vioxx costs
Executive Summary
The Attorney General of Florida filed suit against Merck, claiming the company misrepresented and suppressed evidence about the risks of Vioxx (rofecoxib) and as a result its agencies suffered damages from purchasing the drug. The suit notes that the Florida Medicaid Program alone purchased at least $80 million of the pain reliever. An appeals court recently ruled that shareholders could pursue a securities class action alleging Merck defrauded investors by failing to disclose problems with Vioxx (1"The Pink Sheet," Sept. 15, 2008, p. 17)
You may also be interested in...
Appeals Court Reinstates Vioxx Securities Class Action Against Merck
A federal appeals court concluded that shareholders did not wait too long to bring a securities class action against Merck alleging the company defrauded investors by failing to disclose safety problems with its pain reliever Vioxx
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.